GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications - PACE-CME

GLPRA for CVD risk reduction in obesity and overweight Clinical implications

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Long-term durability of BP control with renal denervation
Long-term durability of BP control with renal denervation
AHA 2023
Long-term durability of BP control with renal denervation
- Michael Bloch, MD
An option for lowering BP beyond prescribing an additional pill
An option for lowering BP beyond prescribing an additional pill
AHA 2023
An option for lowering BP beyond prescribing an additional pill
- Florian Rader, MD
Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine
Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine
AHA 2023
Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine
- Andrew Bellinger, MD, PhD
Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy
Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy
AHA 2023
Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy
- Ahmad Masri, MD